ProfileGDS5678 / 1424133_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 85% 85% 84% 82% 75% 84% 81% 81% 84% 86% 84% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6411380
GSM967853U87-EV human glioblastoma xenograft - Control 26.3941385
GSM967854U87-EV human glioblastoma xenograft - Control 36.3535485
GSM967855U87-EV human glioblastoma xenograft - Control 46.3674384
GSM967856U87-EV human glioblastoma xenograft - Control 56.0402382
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8768875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.986584
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8353781
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8448381
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2111384
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5303686
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2978384
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2073684
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1185183